157 related articles for article (PubMed ID: 30621480)
21. Targeted therapy of octreotide-modified oleanolic acid liposomes to somatostatin receptor overexpressing tumor cells.
Wang Q; Zhu R; Wang M; Xing S; Li L; He Y; Cao W; Gao D
Nanomedicine (Lond); 2017 Apr; 12(8):927-940. PubMed ID: 28338414
[TBL] [Abstract][Full Text] [Related]
22. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
[TBL] [Abstract][Full Text] [Related]
23. Novel molecular beacons to monitor microRNAs in non-small-cell lung cancer.
Yao Q; Zhang AM; Ma H; Lin S; Wang XX; Sun JG; Chen ZT
Mol Cell Probes; 2012 Oct; 26(5):182-7. PubMed ID: 22796123
[TBL] [Abstract][Full Text] [Related]
24. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
Li H; Yuan D; Sun M; Ping Q
Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
[TBL] [Abstract][Full Text] [Related]
25. SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line.
Seifi-Najmi M; Hajivalili M; Safaralizadeh R; Sadreddini S; Esmaeili S; Razavi R; Ahmadi M; Mikaeili H; Baradaran B; Shams-Asenjan K; Yousefi M
Cell Mol Biol (Noisy-le-grand); 2016 Sep; 62(11):87-94. PubMed ID: 27755958
[TBL] [Abstract][Full Text] [Related]
26. Development of an inhalable, stimuli-responsive particulate system for delivery to deep lung tissue.
Abbas Y; Azzazy HM; Tammam S; Lamprecht A; Ali ME; Schmidt A; Sollazzo S; Mathur S
Colloids Surf B Biointerfaces; 2016 Oct; 146():19-30. PubMed ID: 27244047
[TBL] [Abstract][Full Text] [Related]
27. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD
Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy.
Banerjee I; De K; Mukherjee D; Dey G; Chattopadhyay S; Mukherjee M; Mandal M; Bandyopadhyay AK; Gupta A; Ganguly S; Misra M
Acta Biomater; 2016 Jul; 38():69-81. PubMed ID: 27109765
[TBL] [Abstract][Full Text] [Related]
30. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
31. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor.
Yang R; Shim WS; Cui FD; Cheng G; Han X; Jin QR; Kim DD; Chung SJ; Shim CK
Int J Pharm; 2009 Apr; 371(1-2):142-7. PubMed ID: 19118614
[TBL] [Abstract][Full Text] [Related]
32. Glycyrrhizin conjugated chitosan nanoparticles for hepatocyte-targeted delivery of lamivudine.
Mishra D; Jain N; Rajoriya V; Jain AK
J Pharm Pharmacol; 2014 Aug; 66(8):1082-93. PubMed ID: 24641311
[TBL] [Abstract][Full Text] [Related]
33. Demethoxycurcumin-carrying chitosan-antibody core-shell nanoparticles with multitherapeutic efficacy toward malignant A549 lung tumor: from in vitro characterization to in vivo evaluation.
Huang WT; Larsson M; Wang YJ; Chiou SH; Lin HY; Liu DM
Mol Pharm; 2015 Apr; 12(4):1242-9. PubMed ID: 25760774
[TBL] [Abstract][Full Text] [Related]
34. Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner.
Li X; Du X; Huo T; Liu X; Zhang S; Yuan F
Acta Radiol; 2009 Jul; 50(6):583-94. PubMed ID: 19449236
[TBL] [Abstract][Full Text] [Related]
35. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles.
Hwang HY; Kim IS; Kwon IC; Kim YH
J Control Release; 2008 May; 128(1):23-31. PubMed ID: 18374444
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia-sensitive bis(2-(2'-benzothienyl)pyridinato-N,C(3'))iridium[poly(n-butyl cyanoacrylate]/chitosan nanoparticles and their phosphorescence tumor imaging in vitro and in vivo.
Zeng Y; Zhang S; Jia M; Liu Y; Shang J; Guo Y; Xu J; Wu D
Nanoscale; 2013 Dec; 5(24):12633-44. PubMed ID: 24177494
[TBL] [Abstract][Full Text] [Related]
37. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
38. Dual drug-loaded biofunctionalized amphiphilic chitosan nanoparticles: Enhanced synergy between cisplatin and demethoxycurcumin against multidrug-resistant stem-like lung cancer cells.
Huang WT; Larsson M; Lee YC; Liu DM; Chiou GY
Eur J Pharm Biopharm; 2016 Dec; 109():165-173. PubMed ID: 27793756
[TBL] [Abstract][Full Text] [Related]
39. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
40. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles.
Wang J; Tao X; Zhang Y; Wei D; Ren Y
Biomaterials; 2010 May; 31(15):4426-33. PubMed ID: 20188412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
